Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | RO7247669 |
Trade Name | |
Synonyms | RO-7247669|RO 7247669|tobemstomig |
Drug Descriptions |
RO7247669 is a bispecific antibody that targets both PD-1 (PDCD1; CD279) and LAG3, potentially resulting in restoration of T-lymphocyte function and antitumor activity (Annals of Oncology 33 (2022): S884-S885). |
DrugClasses | LAG3 Antibody 18 PD-L1/PD-1 antibody 121 |
CAS Registry Number | 2648839-43-2 |
NCIT ID | C173539 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
Axitinib + RO7247669 | Axitinib RO7247669 | 0 | 1 |
Axitinib + RO7247669 + Tiragolumab | Axitinib RO7247669 Tiragolumab | 0 | 1 |
Bevacizumab + RO7247669 | Bevacizumab RO7247669 | 0 | 1 |
Carboplatin + Paclitaxel + RO7247669 | Carboplatin Paclitaxel RO7247669 | 0 | 1 |
Carboplatin + Pemetrexed Disodium + RO7247669 | Carboplatin Pemetrexed Disodium RO7247669 | 0 | 1 |
Nab-paclitaxel + RO7247669 | Nab-paclitaxel RO7247669 | 0 | 1 |
Pemetrexed Disodium + RO7247669 | Pemetrexed Disodium RO7247669 | 0 | 1 |
RO7247669 | RO7247669 | 0 | 6 |
RO7247669 + Tiragolumab | RO7247669 Tiragolumab | 0 | 2 |